# Depemokimab PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/depemokimab

> The next catalyst for depemokimab, sponsored by GSK plc (GSK), is its primary completion, March 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | depemokimab |
| Codes | GSK3511294 |
| Sponsor | GSK plc (GSK) https://sec-api.dev/companies/gsk/catalysts |
| Indications | [Asthma](https://sec-api.dev/indications/asthma), [Hypereosinophilic Syndrome](https://sec-api.dev/indications/hypereosinophilic-syndrome), [Pulmonary Disease, Chronic Obstructive](https://sec-api.dev/indications/pulmonary-disease-chronic-obstructive) |
| Modality |  |
| FDA designations | none disclosed |

## Timeline

### March 2027: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Asthma.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07671001 (A Study of Depemokimab in Participants of 6 to 11 Years of Age): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-03-01 (ESTIMATED); Lead Sponsor GlaxoSmithKline." https://clinicaltrials.gov/study/NCT07671001

### Mar to Jun 2027: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Asthma.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07671001 (A Study of Depemokimab in Participants of 6 to 11 Years of Age): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-03-01 (ESTIMATED); Lead Sponsor GlaxoSmithKline." https://clinicaltrials.gov/study/NCT07671001

### Oct 2027 to Jan 2028: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Hypereosinophilic Syndrome.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05334368 (Depemokimab in Participants With Hypereosinophilic Syndrome, Efficacy, and Safety Trial): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-10-29 (ESTIMATED); Lead Sponsor GlaxoSmithKline." https://clinicaltrials.gov/study/NCT05334368

### October 2027: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Hypereosinophilic Syndrome.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05334368 (Depemokimab in Participants With Hypereosinophilic Syndrome, Efficacy, and Safety Trial): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-10-29 (ESTIMATED); Lead Sponsor GlaxoSmithKline." https://clinicaltrials.gov/study/NCT05334368

### Jan to Apr 2028: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Asthma.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06979323 (Depemokimab Asthma Imaging and Bronchoscopy Sub-Study): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-01-05 (ESTIMATED); Lead Sponsor GlaxoSmithKline." https://clinicaltrials.gov/study/NCT06979323

### January 2028: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Asthma.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06979323 (Depemokimab Asthma Imaging and Bronchoscopy Sub-Study): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-01-05 (ESTIMATED); Lead Sponsor GlaxoSmithKline." https://clinicaltrials.gov/study/NCT06979323

### Dec 2028 to Mar 2029: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Pulmonary Disease, Chronic Obstructive.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06959095 (Depemokimab as an Extended Treatment Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-12-13 (ESTIMATED); Lead Sponsor GlaxoSmithKline." https://clinicaltrials.gov/study/NCT06959095

### Dec 2028 to Mar 2029: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Pulmonary Disease, Chronic Obstructive.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06961214 (Depemokimab as an Extended Treatment Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA-2)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-12-13 (ESTIMATED); Lead Sponsor GlaxoSmithKline." https://clinicaltrials.gov/study/NCT06961214

### December 2028: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Pulmonary Disease, Chronic Obstructive.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06959095 (Depemokimab as an Extended Treatment Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-12-13 (ESTIMATED); Lead Sponsor GlaxoSmithKline." https://clinicaltrials.gov/study/NCT06959095

### December 2028: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Pulmonary Disease, Chronic Obstructive.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06961214 (Depemokimab as an Extended Treatment Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA-2)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-12-13 (ESTIMATED); Lead Sponsor GlaxoSmithKline." https://clinicaltrials.gov/study/NCT06961214

### Apr to Jul 2029: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Pulmonary Disease, Chronic Obstructive.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07177339 (eValuating the Efficacy and Safety of InitiatinG depemokImab earLy therApy iN Chronic Obstructive Pulmonary Disorder (COPD) With Type 2 Inflammation): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-04-30 (ESTIMATED); Lead Sponsor GlaxoSmithKline." https://clinicaltrials.gov/study/NCT07177339

### April 2029: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Pulmonary Disease, Chronic Obstructive.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07177339 (eValuating the Efficacy and Safety of InitiatinG depemokImab earLy therApy iN Chronic Obstructive Pulmonary Disorder (COPD) With Type 2 Inflammation): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-04-30 (ESTIMATED); Lead Sponsor GlaxoSmithKline." https://clinicaltrials.gov/study/NCT07177339

### Sep to Dec 2030: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Asthma.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07456033 (A Study of Efficacy and Safety of Depemokimab Compared With Placebo in Adults and Adolescents With at Risk Type 2 Asthma): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2030-09-23 (ESTIMATED); Lead Sponsor GlaxoSmithKline." https://clinicaltrials.gov/study/NCT07456033

### September 2030: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Asthma.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07456033 (A Study of Efficacy and Safety of Depemokimab Compared With Placebo in Adults and Adolescents With at Risk Type 2 Asthma): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2030-09-23 (ESTIMATED); Lead Sponsor GlaxoSmithKline." https://clinicaltrials.gov/study/NCT07456033

## Same indication

- [Amlitelimab](https://sec-api.dev/pdufa/amlitelimab) (SNY)
- [Aro-rage](https://sec-api.dev/pdufa/aro-rage) (ARWR)
- [Atuliflapon](https://sec-api.dev/pdufa/atuliflapon) (AZN)
- [AZD4604](https://sec-api.dev/pdufa/azd4604) (AZN)
- [AZD8630](https://sec-api.dev/pdufa/azd8630) (AZN)
- [Bda mdi](https://sec-api.dev/pdufa/bda-mdi) (AZN)
- [Bda mdi hfo 160/180 μg](https://sec-api.dev/pdufa/bda-mdi-hfo-160) (AZN)
- [Fasenra (benralizumab)](https://sec-api.dev/pdufa/benralizumab) (AZN)
- [Bff mdi](https://sec-api.dev/pdufa/bff-mdi) (AZN)
- [Brenipatide](https://sec-api.dev/pdufa/brenipatide) (LLY)
- [Budesonide/albuterol metered dose inhaler, mdi](https://sec-api.dev/pdufa/budesonide-albuterol-metered-dose-inhaler-mdi) (AZN)
- [Ohtuvayre (ensifentrine)](https://sec-api.dev/pdufa/ensifentrine) (MRK)
- [Ff/umec/vi](https://sec-api.dev/pdufa/ff-umec-vi) (GSK)
- [Fp/abs](https://sec-api.dev/pdufa/fp-abs) (TEVA)
- [Qbrexza (glycopyrronium tosylate)](https://sec-api.dev/pdufa/glycopyrronium) (DERM)
- [Gp mdi](https://sec-api.dev/pdufa/gp-mdi) (AZN)
- [Gsk3511294 (depemokimab)](https://sec-api.dev/pdufa/gsk3511294-depemokimab) (GSK)
- [GSK3862995B](https://sec-api.dev/pdufa/gsk3862995b) (GSK)
- [GSK5784283](https://sec-api.dev/pdufa/gsk5784283) (GSK)
- [HFA-152A](https://sec-api.dev/pdufa/hfa-152a) (GSK)
- [Intervention: as mdi](https://sec-api.dev/pdufa/intervention-as-mdi) (AZN)
- [JNJ-95597528](https://sec-api.dev/pdufa/jnj-95597528) (JNJ)
- [Londamocitinib](https://sec-api.dev/pdufa/londamocitinib) (AZN)
- [Lunsekimig](https://sec-api.dev/pdufa/lunsekimig) (SNY)
- [Nucala (mepolizumab)](https://sec-api.dev/pdufa/mepolizumab) (GSK)
- [Pf-07275315 dose 1](https://sec-api.dev/pdufa/pf-07275315) (PFE)
- [QMF149](https://sec-api.dev/pdufa/qmf149) (NVS)
- [QVM149](https://sec-api.dev/pdufa/qvm149) (NVS)
- [Rocatinlimab](https://sec-api.dev/pdufa/rocatinlimab) (AMGN)
- [Salbutamol hfa-134a](https://sec-api.dev/pdufa/salbutamol-hfa-134a) (GSK)
- [TEV-56248](https://sec-api.dev/pdufa/tev-56248) (TEVA)
- [TEZSPIRE® (tezepelumab)](https://sec-api.dev/pdufa/tezepelumab) (AZN)
- [Tilrekimig](https://sec-api.dev/pdufa/tilrekimig) (PFE)
- [Tozorakimab](https://sec-api.dev/pdufa/tozorakimab) (AZN)
- [WIN378](https://sec-api.dev/pdufa/win378) (WWB)

Calendar months: [March 2027](https://sec-api.dev/fda-calendar/2027-03), [October 2027](https://sec-api.dev/fda-calendar/2027-10), [January 2028](https://sec-api.dev/fda-calendar/2028-01)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/depemokimab.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Depemokimab PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/depemokimab

```bibtex
@misc{secapidev_pdufa_depemokimab_20261116,
  title        = {Depemokimab PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/depemokimab}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_depemokimab_20261116","title":"Depemokimab PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/depemokimab","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
